Media Coverage

AI-Driven Solutions Poised for Big Impact on Drug Discovery

researcher in futuristic laboratory using artificial intelligence for drug discovery


Biocompare recently asked three experts what they thought about the use of artificial intelligence and machine learning in drug discovery, a topic that has been front and center lately, discussed regularly at scientific meetings as well as in mainstream publications. In the Q&A, Grant Wishart, Ph.D., Director CADD & Structural Biology at Charles River Laboratories; Stephan Steigele, Ph.D., Head of Science Genedata; and Matt Segall, Ph.D., CEO at Optibrium, share their considerable insights and thoughts on the future.

Read Full Q&A Session